As Amgen strives to become the top player in cardiometabolic risk reduction by the start of the next decade, the company took to the American Diabetes Association 2026 Scientific Sessions in New Orleans this past weekend to bolster the case for its cholesterol-lowering blockbuster Repatha in a high-risk patient subgroup….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
